Investors
We are committed to delivering our strategy and creating value for our shareholders.
Latest News
Latest Events
Verona Pharma to Present at H.C. Wainwright 24th Annual Global Investment Conference
LONDON and RALEIGH, N.C., Aug. 29, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), announces that senior management will present a company overview at the H.C. Wainwright 24 th Annual Global Investment Conference on Monday, September 12, 2022 at 2:00 PM
Verona Pharma Strengthens Commercialization Leadership Team
LONDON and RALEIGH, N.C., Aug. 24, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on respiratory diseases, continues its preparation for commercialization with appointments of Matthew Casbon, Vice
Nuance Pharma receives Clearance to begin Pivotal Clinical Trials with Ensifentrine for COPD in China
LONDON and RALEIGH, N.C., Aug. 19, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces its development partner, Nuance Pharma, has received clearance from the Center of
Discover More
Verona Pharma
Investor Information
© Verona Pharma plc 2022. All rights reserved